Outcomes of 50 Patients With Ewing Sarcoma Family of Tumors Treated at a Single Institution in Taiwan. Issue 22 (May 2016)

• Record Type: Journal Article
• Authors: Lee, Chih-Ying; Yen, Chueh-Chuan; Yen, Hsiu-Ju; Shiau, Cheng-Ying; Chao, Ta-Chung; Wu, Po-Kuei; Chen, Cheng-Fong; Chen, Paul Chih-Hsueh; Wu, Hung-Ta Hondar; Chiou, Hong-Jen; Chen, Chao-Chun; Hung, Giun-Yi; Chen, Wei-Ming
• Other Names: He. Shihan section editor.
• Is Part Of: Medicine. Volume 95:Issue 22(2016)
• Publication Date: 2016-05
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000003830
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: To identify the prognostic factors and long-term outcome of the Ewing sarcoma family of tumors (ESFT), data on 50 patients with ESFT treated at Taipei Veterans General Hospital between February 1991 and March 2014 were retrospectively considered. The influence of patient demographics, tumor features, and clinical and therapeutic parameters on overall survival (OS) and progression-free survival (PFS) rates were assessed. The results revealed that 21 of the 50 patients (42%) were metastatic at diagnosis. The median follow-up time was 1.8 years. The 5-year OS and PFS for patients who were nonmetastatic were 61.6% and 55.5%, respectively, and 18.8% and 15.4% for patients who were metastatic, respectively. The key adverse prognostic factor was metastasis at diagnosis. Radiotherapy for local control was associated with improved PFS. The high rate of primary metastasis and poorer outcomes of nonmetastatic ESFT compared with results from Western studies, along with previously reported low rates of ESFT in Taiwanese people, suggest that genetic factors play a role in the pathogenesis of ESFT and chemotherapy pharmacokinetics and pharmacodynamics. Radiotherapy in local treatment should be considered more aggressively in Taiwanese patients with ESFT.